DE1080265B - Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances - Google Patents

Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances

Info

Publication number
DE1080265B
DE1080265B DEF26694A DEF0026694A DE1080265B DE 1080265 B DE1080265 B DE 1080265B DE F26694 A DEF26694 A DE F26694A DE F0026694 A DEF0026694 A DE F0026694A DE 1080265 B DE1080265 B DE 1080265B
Authority
DE
Germany
Prior art keywords
active ingredients
production
pharmaceutical preparations
substances
protracted effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DEF26694A
Other languages
German (de)
Inventor
Dr Werner Scholtan
Dr Georg Matthaeus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to DEF26694A priority Critical patent/DE1080265B/en
Publication of DE1080265B publication Critical patent/DE1080265B/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Description

Verfahren zur Herstellung von oral anzuwendenden Arzneimittelzubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen Zur Herstellung von Arzneimitteln mit protrahierter Wirkung sind bisher eine große Anzahl von Überzugstoffen verwendet worden. Vor allem sind für die' sen Zweck hochmolekulare Stoffe der verschiedensten Art verwendet worden, wie z. B. Cellulosederivate und Polyvinylverbindungen (vgl. USA.-Patentschrift 2805977). Process for the production of pharmaceutical preparations for oral use with protracted effect from active ingredients and protective substances for the production of Medicinal products with a protracted effect have hitherto been a large number of coating substances been used. Above all, high-molecular substances are of the most varied for this purpose Kind been used, such as. B. cellulose derivatives and polyvinyl compounds (cf. U.S. Patent 2805977).

Da die Arzneimittelzubereitungen mit protrahierter Wirkung meist dadurch hergestellt werden, daß zunächst eine Lösung des Kunststoffes in einem organischen Lösungsmittel bereitet wird, in der das Arzneimittel dann suspendiert wird oder die auf das Arzneimittel aufgesprüht wird, so ist bei diesen Stoffen die Löslichkeit in organischen Lösungsmitteln Voraussetzung. Since the drug preparations with a protracted effect mostly be prepared in that first a solution of the plastic in an organic Solvent is prepared in which the drug is then suspended or which is sprayed onto the drug, so is the solubility of these substances in organic solvents is a prerequisite.

Weitere Voraussetzungen sind folgende: Die in Frage kommenden Stoffe müssen absolut ungiftig und gut verträglich sein. Sie müssen ferner entweder im Magen oder im Darm aufgespalten werden, damit das Arzneimittel auch resorbiert werden kann. Schließlich muß der Umhüllungsstoff eine hartwachsartige Kosistenz besitzen, um gegen mechanische Beanspruchungen genügend widerstandsfähig zu sein, so daß flüssige und spröde kristalline Stoffe ungeeignet sind. Further requirements are the following: The substances in question must be absolutely non-toxic and well tolerated. You must also either be in the The stomach or intestines are split open so that the medicine is also absorbed can. Finally, the wrapping material must have a hard waxy consistency, to be sufficiently resistant to mechanical stress, so that liquid and brittle crystalline substances are unsuitable.

Der Umhüllungsstoff muß chemisch beständig sein und darf nicht mit dem Arzneimittel reagieren.The wrapping material must be chemically resistant and must not be with react to the drug.

Es wurde nun überraschenderweise festgestellt, daß die Fettsäureester der Zucker diese Eigenschaften eines Umhüllungsstoffes besitzen, und es wurde gefunden, daß man oral anzuwendende Arzneimittelzubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen dadurch herstellen kann, daß man Wirkstoffe mit wasserschwerlöslichen FettsäureesternvonDi- und Trisacchariden überzieht und die umhüllten Stoffe zu Tabletten verpreßt oder zu Suspensionen weiterverarbeitet. It has now surprisingly been found that the fatty acid esters the sugar have these properties of a coating material, and it has been found that you can use orally administered pharmaceutical preparations with a protracted effect Active ingredients and protective substances can be produced by using active ingredients with sparingly soluble substances Fatty acid esters of di- and trisaccharides coats and the coated substances form tablets pressed or processed into suspensions.

Die Resorption der Arzneimittel kann dadurch verändert werden, daß den Fettsäureestern der Di- und Trisaccharide Fettsäuren, Glycerinester von Fettsäuren, niedrigschmelzende Wachse, wie z. B. Paraffinwachs oder Bienenwachs, sowie Lipoide, wie z. B. The absorption of the drug can be changed by the fact that the fatty acid esters of the di- and trisaccharides fatty acids, glycerol esters of fatty acids, low melting waxes, such as. B. paraffin wax or beeswax, as well as lipoids, such as B.

Lecithin und Cholesterin, oder wasserlösliche bzw. wasserdispergierbare Fettsäureester von Di- und Trisacchariden zugesetzt werden.Lecithin and cholesterol, or water-soluble or water-dispersible Fatty acid esters of di- and trisaccharides are added.

Bei der Herstellung der umhüllten Wirkstoffe kann es zweckmäßig sein, daß man den geschmolzenen Umhüllungsstoffen zusätzlich noch Netzmittel zusetzt, um dadurch eine bessere Benetzung des Wirkstoffs herbeizuführen. Als Netzmittel können vorzugsweise nichtionogene Emulgatoren verwendet werden. In the production of the coated active ingredients, it can be useful that wetting agents are additionally added to the molten coating materials, in order to bring about a better wetting of the active ingredient. As a wetting agent preferably non-ionic emulsifiers can be used.

Die vorgenannten wasserschwerlöslichen, wasserlöslichen und leicht dispergierbaren Fettsäureester von Di- und Trisacchariden sind bekannt, und zwar aus: L. Osip-ow, D. Marra und W. C. York, Soap and Chem. Special, 1956, S. 1, L. Osipow, Parfums, Cosmetiques, Savons, 131, 5. 17 (1957), L. Osipow, F. D. Snell und W. C. York, Ind. The aforementioned water-sparingly soluble, water-soluble and easily dispersible fatty acid esters of di- and trisaccharides are known, namely from: L. Osip-ow, D. Marra and W. C. York, Soap and Chem. Special, 1956, p. 1, L. Osipow, Parfums, Cosmetiques, Savons, 131, 5.17 (1957), L. Osipow, F.D. Snell and W. C. York, Ind.

Eng. Chem., 48, S. 1459 (1956), L. Osipow, F. D. Snell und A. Finchler, J.Am.OilChem.Closely. Chem., 48, p. 1459 (1956), L. Osipow, F. D. Snell and A. Finchler, J.Am.OilChem.

Soc., 33, S. 424 (1956), 34, S. 185 (1957), 35, S.65 und 127 (1958).Soc., 33, p. 424 (1956), 34, p. 185 (1957), 35, p. 65 and 127 (1958).

Daß die Fettsäureester der Zucker für den beanspruchten Zweck geeignet sein würden, war durchaus überraschend, da eine große Anzahl anderer Fettsäureester als Umhüllungsstoff völlig ungeeignet ist, wie z. B. Isopropylpalmitat, die Fettöle, die Fette selbst usw. That the fatty acid ester of the sugar is suitable for the claimed purpose was quite surprising as a large number of other fatty acid esters would be is completely unsuitable as a wrapping material, such as. B. Isopropyl palmitate, the fatty oils, the fats themselves, etc.

Die erfindungsgemäß verwendeten Zuckerester besitzen auch gerade die gewünschte Aufspaltbarkeit durch Enzyme. Sie ist überraschend gering, und nur ein kleiner Teil der Verbindung wird unter physiologischen Bedingungen tatsächlich aufgespalten. Diese teilweise Spaltbarkeit genügt jedoch, um die Resorption des Arzneimittels im Organismus zu gewährleisten. Eine zu schnelle Spaltbarkeit würde dagegen einen nachteiligen Einfluß auf die protrahierte Wirkung ausüben. The sugar esters used according to the invention also have straight the desired splittability by enzymes. It is surprisingly small, and only a small part of the compound actually becomes under physiological conditions split up. However, this partial cleavage is sufficient to ensure the resorption of the To ensure the drug in the organism. Too fast a cleavage would on the other hand, exert a detrimental influence on the protracted effect.

Ein sehr wesentlicher Vorteil der beanspruchten Zuckerester ist auch die Tatsache, daß bei ihrer Spaltung physiologische B ruchstücke entstehen. Durch diese zwar nicht unerwartete, aber sehr vorteilhafte Eigenschaft zeichnen sich die Zuckerester vor allen anderen Umhüllungsstoffen aus. A very significant advantage of the claimed sugar esters is also the fact that when they split up, physiological fragments are created. By this property, although not unexpected, is very advantageous Sugar esters from all other wrapping materials.

Die erfindungsgemäß verwendeten Überzugstoffe erlauben es, eine Umhüllung von Wirkstoffen auch ohne vorhergehendes Lösen in organischen Lösungsmitteln herzustellen, so daß bei Verwendung dieser Stoffe wirtschaftlicher gearbeit werden kann. The coating materials used according to the invention allow a covering of active ingredients even without prior dissolving in organic solvents to manufacture so that you can work more economically when using these substances.

Die Herstellung der Überzüge kann dadurch vorgenommen werden, daß man das Arzneimittel in dem geschmolzenen Überzugsmaterial dispergiert und anschließend bei hoher Temperatur in einem Zerstäubungstrockner zerstäubt, oder dadurch, daß das Arzneimittel bei hoher Temperatur mittels einer Mischvorrichtung (Schnecke) mit dem Umhüllungsstoff vermischt wird. In diesem Falle muß das erhaltene Produkt nach dem Erkalten in einer Mühle zu einem Pulver vermahlen werden. The coatings can be produced in that the drug is dispersed in the molten coating material and then atomized at high temperature in an atomization dryer, or by the fact that the drug at high temperature by means of a mixing device (screw) is mixed with the wrapping material. In this case the product obtained must be ground to a powder in a grinder after cooling.

Die nach den verschiedenen Verfahren erhaltenen Pulver können entweder als solche verwendet oder anschließend granuliert oder zu Tabletten verpreßt oder in Wasser unter Verwendung von Suspensionshilfsstoffen zu einer Suspension weiterverarbeitet werden. The powders obtained by the various processes can either used as such or subsequently granulated or compressed into tablets or processed into a suspension in water using suspension auxiliaries will.

Gegenüber den reinen Arzneistoffen besitzen die so hergesfellten Produkte, wie Tierversuche ergaben, eine gute protrahierte Wirkung. Compared to the pure medicinal substances, those produced in this way have Products, as shown by animal testing, have a good protracted effect.

Beispiel 120 g Saccharosepentastearat werden durch Erhitzen auf 1000 C geschmolzen. In diese Schmelze werden 100 g 2- [41-Aminobenzolsulfonamidoj -4-methylpyrimidin dispergiert. Die Suspension wird anschließend bei 1000 C durch Zerstäubung in einem Zerstäubungstrockner in ein trockenes Pulver übergeführt. Example 120 g of sucrose pentastearate are made by heating to 1000 C melted. 100 g of 2- [41-aminobenzenesulfonamidoj -4-methylpyrimidine are added to this melt dispersed. The suspension is then at 1000 C by atomization in a Atomization dryers converted into a dry powder.

PATENTANSPROCHE: 1. Verfahren zur Herstellung von oral anzuwendenden Arzneimittelzubereitungen mit protrahierter Wirkung aus Wirkstoffen und Schutzstoffen, dadurch gekennzeichnet, daß man Wirkstoffe mit v.asserschwerlöslichen Fettsäureestern von Di- und Trisacchariden überzieht und die umhüllten Stoffe zu Tabletten verpreßt oder zu Suspensionen weiterverarbeitet. PATENT CLAIMS: 1. Process for the preparation of orally administered Medicinal preparations with a protracted effect from active ingredients and protective substances, characterized in that active ingredients with partially water-sparingly soluble fatty acid esters coated with di- and trisaccharides and pressed the coated substances into tablets or processed into suspensions.

Claims (1)

2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß man den Fettsäureestern der Di-und Trisaccharide Fettsäuren, Glycerinester von Fettsäuren, niedrigschmelzende Wachse, Lipoide oder wasserlösliche bzw. wasserdispergierbare Fettsäureester von Di- und Trisacchariden zusetzt. 2. The method according to claim 1, characterized in that the Fatty acid esters of di- and trisaccharides fatty acids, glycerol esters of fatty acids, low-melting waxes, lipids or water-soluble or water-dispersible ones Adds fatty acid esters of di- and trisaccharides. 3. Verfahren nach Anspruch 1 und 2, dadurch gekennzeichnet, daß man der als Umhüllungsstoff verwendeten Mischung nichtionogene Emulgatoren zusetzt. 3. The method according to claim 1 and 2, characterized in that one adding nonionic emulsifiers to the mixture used as the coating material. In Betracht gezogene Druckschriften: Deutsche Patentschrift Nr. 939283; USA.-Patentschriften Nr. 2698822, 2805 977; Chemisches Zentralblatt, 1957, 9721, Miccicke. Documents considered: German Patent No. 939283; U.S. Patent Nos. 2698822, 2805 977; Chemisches Zentralblatt, 1957, 9721, Miccicke.
DEF26694A 1958-09-30 1958-09-30 Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances Pending DE1080265B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEF26694A DE1080265B (en) 1958-09-30 1958-09-30 Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEF26694A DE1080265B (en) 1958-09-30 1958-09-30 Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances

Publications (1)

Publication Number Publication Date
DE1080265B true DE1080265B (en) 1960-04-21

Family

ID=7092120

Family Applications (1)

Application Number Title Priority Date Filing Date
DEF26694A Pending DE1080265B (en) 1958-09-30 1958-09-30 Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances

Country Status (1)

Country Link
DE (1) DE1080265B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380534A (en) * 1980-04-07 1983-04-19 Yamanouchi Pharmaceutical Co., Ltd. Solid drug preparations
EP0195476A2 (en) * 1985-03-21 1986-09-24 The Procter & Gamble Company Therapeutic particles
EP0230332A1 (en) * 1986-01-13 1987-07-29 N.V. Sanico A pharmaceutical composition with sustained release of the active component and a process for the preparation thereof
US4960595A (en) * 1984-11-06 1990-10-02 Daiichi Seiyaku Co., Ltd. Lipid membrane structures
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US8168223B1 (en) 1997-09-29 2012-05-01 Novartis Pharma Ag Engineered particles and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US8709484B2 (en) 2000-05-10 2014-04-29 Novartis Ag Phospholipid-based powders for drug delivery
US8715623B2 (en) 2001-12-19 2014-05-06 Novartis Ag Pulmonary delivery of aminoglycoside
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
DE939283C (en) * 1948-10-02 1956-02-16 August Luhn & Co G M B H Manufacture of ointments and skin lotions
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE939283C (en) * 1948-10-02 1956-02-16 August Luhn & Co G M B H Manufacture of ointments and skin lotions
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4380534A (en) * 1980-04-07 1983-04-19 Yamanouchi Pharmaceutical Co., Ltd. Solid drug preparations
US4960595A (en) * 1984-11-06 1990-10-02 Daiichi Seiyaku Co., Ltd. Lipid membrane structures
EP0195476A2 (en) * 1985-03-21 1986-09-24 The Procter & Gamble Company Therapeutic particles
EP0195476A3 (en) * 1985-03-21 1987-05-27 The Procter & Gamble Company Therapeutic particles
EP0230332A1 (en) * 1986-01-13 1987-07-29 N.V. Sanico A pharmaceutical composition with sustained release of the active component and a process for the preparation thereof
EP1138337A3 (en) * 1994-08-04 2003-03-26 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
EP1138337A2 (en) * 1994-08-04 2001-10-04 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
EP1138319A2 (en) * 1994-08-04 2001-10-04 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
EP1138319A3 (en) * 1994-08-04 2003-03-19 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6811792B2 (en) 1994-12-02 2004-11-02 Quadrant Drug Delivery Ltd. Solid dose delivery vehicle and methods of making same
US6565871B2 (en) 1994-12-02 2003-05-20 Elan Drug Delivery Ltd. Solid dose delivery vehicle and methods of making same
US6331310B1 (en) 1994-12-02 2001-12-18 Quadrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6893657B2 (en) 1994-12-02 2005-05-17 Quadrant Drug Delivery Ltd. Solid dose delivery vehicle and methods of making same
US7056495B2 (en) 1994-12-02 2006-06-06 Quadrant Drug Delivery Ltd. Solid dose delivery vehicle and methods of making same
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7780991B2 (en) 1994-12-02 2010-08-24 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7785631B2 (en) 1994-12-02 2010-08-31 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US8168223B1 (en) 1997-09-29 2012-05-01 Novartis Pharma Ag Engineered particles and methods of use
US9554993B2 (en) 1997-09-29 2017-01-31 Novartis Ag Pulmonary delivery particles comprising an active agent
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US8709484B2 (en) 2000-05-10 2014-04-29 Novartis Ag Phospholipid-based powders for drug delivery
US8877162B2 (en) 2000-05-10 2014-11-04 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery
US8715623B2 (en) 2001-12-19 2014-05-06 Novartis Ag Pulmonary delivery of aminoglycoside
US9421166B2 (en) 2001-12-19 2016-08-23 Novartis Ag Pulmonary delivery of aminoglycoside

Similar Documents

Publication Publication Date Title
DE69915798T2 (en) IMPROVING COMPOSITION BASED ON JOJOBA ESTER
DE1106454B (en) Coating agents for drugs
DE3826946C1 (en)
DE1080265B (en) Process for the production of orally used pharmaceutical preparations with a protracted effect from active ingredients and protective substances
DE1130556B (en) Process for the manufacture of antimalarial preparations
DE68907335T2 (en) Microgranules loaded with an active ingredient consisting essentially of triglycerides of saturated fatty acids and their external therapeutic use.
EP0250648A2 (en) Pharmaceutical preparation for the sustained release of ibuprofen
DE69627880T2 (en) DILTIAZIC MICROGRANULATES WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES
DE60214207T2 (en) NAIL POLISH CONTAINING TAZAROTES AND USE THEREOF FOR THE TREATMENT AND / OR THE PREVENTION OF PSORIASIS
EP0011718B1 (en) Stable valepotriate compositions and methods of preparing the same
DE4038385C2 (en) Sitosterol and its glycosides with improved bioavailability
DE3878978T2 (en) GALENIC FORM OF A DRY EXTRACT OF PLANTS.
DE2615336B2 (en) Process for obtaining easily absorbable sterling glycoside
DE69003960T2 (en) The use of deacetylated chitin in the manufacture of a medicament for the treatment of inflammatory diseases.
DE69005059T2 (en) Vasodilator.
DE19729143C2 (en) Herbal care ointment
DE68906513T2 (en) PHARMACEUTICAL PREPARATIONS FOR DICLOFENAC.
AT211480B (en) Process for the production of orally administered pharmaceutical preparations with a protracted effect
DE2049935A1 (en) Process for coating tablets with sugar
DE1617309C3 (en) Process for the manufacture of pharmaceutical preparations containing vitamins
EP0310757A1 (en) Manufacturing process of a propolis-ethanol extract
CH156609A (en) Method of making a dry, homeopathic remedy.
DE3637992A1 (en) Hair tonic
DE1417326A1 (en) Process for the production of orally administered pharmaceutical preparations with a protracted effect
DD200347A5 (en) PROCESS FOR PREPARING A CONTAINED ACETYL SALICYL ACID PREPARATION